Brenner H

References (3)

Title : Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus - Lawrenson_2016_Nat.Commun_7_12675
Author(s) : Lawrenson K , Kar S , McCue K , Kuchenbaeker K , Michailidou K , Tyrer J , Beesley J , Ramus SJ , Li Q , Delgado MK , Lee JM , Aittomaki K , Andrulis IL , Anton-Culver H , Arndt V , Arun BK , Arver B , Bandera EV , Barile M , Barkardottir RB , Barrowdale D , Beckmann MW , Benitez J , Berchuck A , Bisogna M , Bjorge L , Blomqvist C , Blot W , Bogdanova N , Bojesen A , Bojesen SE , Bolla MK , Bonanni B , Borresen-Dale AL , Brauch H , Brennan P , Brenner H , Bruinsma F , Brunet J , Buhari SA , Burwinkel B , Butzow R , Buys SS , Cai Q , Caldes T , Campbell I , Canniotto R , Chang-Claude J , Chiquette J , Choi JY , Claes KB , Cook LS , Cox A , Cramer DW , Cross SS , Cybulski C , Czene K , Daly MB , Damiola F , Dansonka-Mieszkowska A , Darabi H , Dennis J , Devilee P , Diez O , Doherty JA , Domchek SM , Dorfling CM , Dork T , Dumont M , Ehrencrona H , Ejlertsen B , Ellis S , Engel C , Lee E , Evans DG , Fasching PA , Feliubadalo L , Figueroa J , Flesch-Janys D , Fletcher O , Flyger H , Foretova L , Fostira F , Foulkes WD , Fridley BL , Friedman E , Frost D , Gambino G , Ganz PA , Garber J , Garcia-Closas M , Gentry-Maharaj A , Ghoussaini M , Giles GG , Glasspool R , Godwin AK , Goldberg MS , Goldgar DE , Gonzalez-Neira A , Goode EL , Goodman MT , Greene MH , Gronwald J , Guenel P , Haiman CA , Hall P , Hallberg E , Hamann U , Hansen TV , Harrington PA , Hartman M , Hassan N , Healey S , Heitz F , Herzog J , Hogdall E , Hogdall CK , Hogervorst FB , Hollestelle A , Hopper JL , Hulick PJ , Huzarski T , Imyanitov EN , Isaacs C , Ito H , Jakubowska A , Janavicius R , Jensen A , John EM , Johnson N , Kabisch M , Kang D , Kapuscinski M , Karlan BY , Khan S , Kiemeney LA , Kjaer SK , Knight JA , Konstantopoulou I , Kosma VM , Kristensen V , Kupryjanczyk J , Kwong A , de la Hoya M , Laitman Y , Lambrechts D , Le N , De Leeneer K , Lester J , Levine DA , Li J , Lindblom A , Long J , Lophatananon A , Loud JT , Lu K , Lubinski J , Mannermaa A , Manoukian S , Le Marchand L , Margolin S , Marme F , Massuger LF , Matsuo K , Mazoyer S , McGuffog L , McLean C , McNeish I , Meindl A , Menon U , Mensenkamp AR , Milne RL , Montagna M , Moysich KB , Muir K , Mulligan AM , Nathanson KL , Ness RB , Neuhausen SL , Nevanlinna H , Nord S , Nussbaum RL , Odunsi K , Offit K , Olah E , Olopade OI , Olson JE , Olswold C , O'Malley D , Orlow I , Orr N , Osorio A , Park SK , Pearce CL , Pejovic T , Peterlongo P , Pfeiler G , Phelan CM , Poole EM , Pylkas K , Radice P , Rantala J , Rashid MU , Rennert G , Rhenius V , Rhiem K , Risch HA , Rodriguez G , Rossing MA , Rudolph A , Salvesen HB , Sangrajrang S , Sawyer EJ , Schildkraut JM , Schmidt MK , Schmutzler RK , Sellers TA , Seynaeve C , Shah M , Shen CY , Shu XO , Sieh W , Singer CF , Sinilnikova OM , Slager S , Song H , Soucy P , Southey MC , Stenmark-Askmalm M , Stoppa-Lyonnet D , Sutter C , Swerdlow A , Tchatchou S , Teixeira MR , Teo SH , Terry KL , Terry MB , Thomassen M , Tibiletti MG , Tihomirova L , Tognazzo S , Toland AE , Tomlinson I , Torres D , Truong T , Tseng CC , Tung N , Tworoger SS , Vachon C , van den Ouweland AM , van Doorn HC , van Rensburg EJ , Van't Veer LJ , Vanderstichele A , Vergote I , Vijai J , Wang Q , Wang-Gohrke S , Weitzel JN , Wentzensen N , Whittemore AS , Wildiers H , Winqvist R , Wu AH , Yannoukakos D , Yoon SY , Yu JC , Zheng W , Zheng Y , Khanna KK , Simard J , Monteiro AN , French JD , Couch FJ , Freedman ML , Easton DF , Dunning AM , Pharoah PD , Edwards SL , Chenevix-Trench G , Antoniou AC , Gayther SA
Ref : Nat Commun , 7 :12675 , 2016
Abstract : A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 x 10(-20)), ER-negative BC (P=1.1 x 10(-13)), BRCA1-associated BC (P=7.7 x 10(-16)) and triple negative BC (P-diff=2 x 10(-5)). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 x 10(-3)) and ABHD8 (P<2 x 10(-3)). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3'-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
ESTHER : Lawrenson_2016_Nat.Commun_7_12675
PubMedSearch : Lawrenson_2016_Nat.Commun_7_12675
PubMedID: 27601076

Title : CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis - Chen_2015_J.Natl.Cancer.Inst_107_
Author(s) : Chen LS , Hung RJ , Baker T , Horton A , Culverhouse R , Saccone N , Cheng I , Deng B , Han Y , Hansen HM , Horsman J , Kim C , Lutz S , Rosenberger A , Aben KK , Andrew AS , Breslau N , Chang SC , Dieffenbach AK , Dienemann H , Frederiksen B , Han J , Hatsukami DK , Johnson EO , Pande M , Wrensch MR , McLaughlin J , Skaug V , van der Heijden HF , Wampfler J , Wenzlaff A , Woll P , Zienolddiny S , Bickeboller H , Brenner H , Duell EJ , Haugen A , Heinrich J , Hokanson JE , Hunter DJ , Kiemeney LA , Lazarus P , Le Marchand L , Liu G , Mayordomo J , Risch A , Schwartz AG , Teare D , Wu X , Wiencke JK , Yang P , Zhang ZF , Spitz MR , Kraft P , Amos CI , Bierut LJ
Ref : J Natl Cancer Inst , 107 : , 2015
Abstract : BACKGROUND: Recent meta-analyses show strong evidence of associations among genetic variants in CHRNA5 on chromosome 15q25, smoking quantity, and lung cancer. This meta-analysis tests whether the CHRNA5 variant rs16969968 predicts age of smoking cessation and age of lung cancer diagnosis.
METHODS: Meta-analyses examined associations between rs16969968, age of quitting smoking, and age of lung cancer diagnosis in 24 studies of European ancestry (n = 29 072). In each dataset, we used Cox regression models to evaluate the association between rs16969968 and the two primary phenotypes (age of smoking cessation among ever smokers and age of lung cancer diagnosis among lung cancer case patients) and the secondary phenotype of smoking duration. Heterogeneity across studies was assessed with the Cochran Q test. All statistical tests were two-sided.
RESULTS: The rs16969968 allele (A) was associated with a lower likelihood of smoking cessation (hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.91 to 0.98, P = .0042), and the AA genotype was associated with a four-year delay in median age of quitting compared with the GG genotype. Among smokers with lung cancer diagnoses, the rs16969968 genotype (AA) was associated with a four-year earlier median age of diagnosis compared with the low-risk genotype (GG) (HR = 1.08, 95% CI = 1.04 to 1.12, P = 1.1*10(-5)). CONCLUSION: These data support the clinical significance of the CHRNA5 variant rs16969968. It predicts delayed smoking cessation and an earlier age of lung cancer diagnosis in this meta-analysis. Given the existing evidence that this CHRNA5 variant predicts favorable response to cessation pharmacotherapy, these findings underscore the potential clinical and public health importance of rs16969968 in CHRNA5 in relation to smoking cessation success and lung cancer risk.
ESTHER : Chen_2015_J.Natl.Cancer.Inst_107_
PubMedSearch : Chen_2015_J.Natl.Cancer.Inst_107_
PubMedID: 25873736

Title : Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases - Ballantyne_2007_Eur.J.Cardiovasc.Prev.Rehabil_14_3
Author(s) : Ballantyne C , Cushman M , Psaty B , Furberg C , Khaw KT , Sandhu M , Oldgren J , Rossi GP , Maiolino G , Cesari M , Lenzini L , James SK , Rimm E , Collins R , Anderson J , Koenig W , Brenner H , Rothenbacher D , Berglund G , Persson M , Berger P , Brilakis E , McConnell JP , Sacco R , Elkind M , Talmud P , Cannon CP , Packard C , Barrett-Connor E , Hofman A , Kardys I , Witteman JC , Criqui M , Corsetti JP , Rainwater DL , Moss AJ , Robins S , Bloomfield H , Collins D , Wassertheil-Smoller S , Ridker P , Danesh J , Gu D , Nelson JJ , Thompson S , Zalewski A , Zariffa N , Di Angelantonio E , Kaptoge S , Thompson A , Walker M , Watson S , Wood A
Ref : Eur J Cardiovasc Prev Rehabil , 14 :3 , 2007
Abstract : BACKGROUND: A large number of observational epidemiological studies have reported generally positive associations between circulating mass and activity levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the risk of cardiovascular diseases. Few studies have been large enough to provide reliable estimates in different circumstances, such as in different subgroups (e.g., by age group, sex, or smoking status) or at different Lp-PLA2 levels. Moreover, most published studies have related disease risk only to baseline values of Lp-PLA2 markers (which can lead to substantial underestimation of any risk relationships because of within-person variability over time) and have used different approaches to adjustment for possible confounding factors. OBJECTIVES: By combination of data from individual participants from all relevant observational studies in a systematic 'meta-analysis', with correction for regression dilution (using available data on serial measurements of Lp-PLA2), the Lp-PLA2 Studies Collaboration will aim to characterize more precisely than has previously been possible the strength and shape of the age and sex-specific associations of plasma Lp-PLA2 with coronary heart disease (and, where data are sufficient, with other vascular diseases, such as ischaemic stroke). It will also help to determine to what extent such associations are independent of possible confounding factors and to explore potential sources of heterogeneity among studies, such as those related to assay methods and study design. It is anticipated that the present collaboration will serve as a framework to investigate related questions on Lp-PLA2 and cardiovascular outcomes. METHODS: A central database is being established containing data on circulating Lp-PLA2 values, sex and other potential confounding factors, age at baseline Lp-PLA2 measurement, age at event or at last follow-up, major vascular morbidity and cause-specific mortality. Information about any repeat measurements of Lp-PLA2 and potential confounding factors has been sought to allow adjustment for possible confounding and correction for regression dilution. The analyses will involve age-specific regression models. Synthesis of the available observational studies of Lp-PLA2 will yield information on a total of about 15 000 cardiovascular disease endpoints.
ESTHER : Ballantyne_2007_Eur.J.Cardiovasc.Prev.Rehabil_14_3
PubMedSearch : Ballantyne_2007_Eur.J.Cardiovasc.Prev.Rehabil_14_3
PubMedID: 17301621
Gene_locus related to this paper: human-PLA2G7